Pharmacy Medical News about colorectal cancer

Your Unread Messages

See All

Hello, Mary O'connor
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer
Medical Oncology, 11/04/09

Paule B et al. – EGFR inhibition by cetuximab may overcome the irinotecan resistance by abrogating drug efflux depending on MDR1 3435 polymorphism. Among patients resistant to irinotecan, it is still possible to use the association of cetuximab plus irinotecan to obtain a complete resection of hepatic metastases that is necessary to improve their survival.

<< Previous
A comparison of ad hoc methods to account for non-cancer AIDS and...

Next >>
Effective Treatment of Patients in a Deep Salvage Situation with...

Colorectal cancer incidence and postmenopausal hormone use by type, recency, and duration in cancer prevention study II
Cancer Epidemiology, Biomarkers & Prevention, 10/28/09 Relevance Score: 72%

Association of IGF1 and IGFBP3 polymorphisms with colorectal polyps and colorectal cancer risk
Cancer Causes and Control, 10/02/09 Relevance Score: 72%

P73 expression and its clinical significance in colorectal cancer
Colorectal Disease, 10/19/09 Relevance Score: 71%

trans-Fatty acid consumption and its association with distal colorectal cancer in the North Carolina Colon Cancer Study II
Cancer Causes and Control, 10/28/09 Relevance Score: 70%

Association of clinicopathological features with UbcH10 expression in colorectal cancer
Journal of Cancer Research & Clinical Oncology, 10/01/09 Relevance Score: 70%